NSTM (NovelStem International) Debt-to-Equity: -0.99 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is NovelStem International Debt-to-Equity?

NovelStem International NSTM Debt-to-Equity is -0.99 as of Mar. 2026. The stock has 2 warning signs investors should review. Among 182 Medical Diagnostics & Research companies, NovelStem International ranks worse than 549450% on this metric.

NovelStem International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $1.93 Mil. NovelStem International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.00 Mil. NovelStem International's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-1.95 Mil. NovelStem International's debt to equity for the quarter that ended in Mar. 2026 was -0.99.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for NovelStem International's Debt-to-Equity or its related term are showing as below:

NSTM' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.91   Med: -0.89   Max: 0.21
Current: -0.99

During the past 13 years, the highest Debt-to-Equity Ratio of NovelStem International was 0.21. The lowest was -2.91. And the median was -0.89.

NSTM's Debt-to-Equity is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 0.33 vs NSTM: -0.99

NovelStem International  (OTCPK:NSTM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

NovelStem International Debt-to-Equity Related Terms

NovelStem International Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for NovelStem International's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovelStem International Debt-to-Equity Chart

NovelStem International Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.15 -1.83 -0.86 -0.89

NovelStem International Quarterly Data
Sep13 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.86 -0.89 -0.89 -0.89 -0.99

NSTM vs NOTVQ, PRPH, IDTA: Debt-to-Equity Comparison

For the Diagnostics & Research subindustry, NovelStem International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovelStem International Debt-to-Equity vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NovelStem International's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where NovelStem International's Debt-to-Equity falls into.


NovelStem International Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

NovelStem International's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.904 + 0) / -2.142
=-0.89

NovelStem International's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.932 + 0) / -1.947
=-0.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.99 mean?
NovelStem International (NSTM) has a Debt-to-Equity of -0.99 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on NovelStem International and its competitors. According to the industry distribution chart, NovelStem International ranks #999999 out of 182 companies in the Medical Diagnostics & Research industry.
Is NovelStem International's Debt-to-Equity too high?
NovelStem International's current Debt-to-Equity is -0.99. Based on the distribution chart, NovelStem International ranks #999999 out of 182 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does NovelStem International's Debt-to-Equity compare to NOTVQ and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, NovelStem International ranks #999999 out of 182 companies for Debt-to-Equity. This places NovelStem International in the lower half of its industry. The industry median Debt-to-Equity is 0.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 182 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on NovelStem International and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NovelStem International's current Debt-to-Equity is -0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovelStem International stock overvalued right now?
NovelStem International (NSTM) has a current Debt-to-Equity of -0.99. The current Debt-to-Equity is -0.99. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For NovelStem International (NSTM), the current Debt-to-Equity is -0.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NovelStem International Business Description

Address 7740 Cavern Lane, Suite 100, Parkland, FL, USA, 33067
NovelStem International Corp is a holding company. Through its subsidiaries, the company is engaged in the development and commercialization of diagnostic technology that can predict patients' anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. The company also has an interest in a book publishing franchise.